CLINICAL AUDIT OF AZITHROMYCIN-BASED THERAPY FOR HELICOBACTER PYLORI INFECTION IN A PEDIATRIC PATIENT AT PRIME CARE HOSPITAL

Abstract

Objective: To evaluate clinical response of azithromycin-based therapy in a pediatric patient with stool antigen–confirmed H. pylori infection.

Methods: A single-patient clinical audit was conducted at Prime Care Hospital. An 8–10-year-old child with positive stool H. pylori antigen received PPI-based triple therapy including azithromycin. Treatment compliance, symptom response, adverse effects, and eradication outcome were assessed.

Results: Partial symptomatic improvement occurred, but repeat stool antigen remained positive. Subsequent guideline-based therapy achieved successful eradication.

Conclusion: Azithromycin-based therapy showed inadequate efficacy. Routine pediatric use is not advised. Standard eradication regimens recommend clarithromycin or bismuth-based therapy; however, azithromycin is occasionally used despite limited pediatric evidence.